NCT03429933View on ClinicalTrials.gov

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

March 2, 2019

Study Completion Date

March 2, 2019

Conditions
Healthy Participants
Interventions
DRUG

BMS-986278

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (2)

9728 NZ

Local Institution, Groningen

SE1 1YR

Local Institution, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03429933 - A Study of Experimental Medication BMS-986278 Given to Healthy Participants | Biotech Hunter | Biotech Hunter